Maarten van der Doelen

Alkaline phosphatase dynamics during radium-223 therapy in mCRPC patients

Prior registered therapies for CRPC Median number of therapies 180 2 [1-3] 139 2 [1-2] 33 2 [1-3] 0.031 None 180 35 (19.4) 139 29 (20.9) 33 4 (12.1) 0.329 Docetaxel 1 180 109 (60.6) 139 82 (59.0) 33 24 (72.7) 0.145 Cabazitaxel 2 180 46 (25.6) 139 30 (21.6) 33 12 (36.4) 0.076 Abiraterone 180 95 (52.8) 139 75 (54.0) 33 16 (48.5) 0.571

Prior SRE 180 90 (50.0) 139 72 (51.8) 33 14 (42.4) 0.333

Age at start of radium-223 [y] 180 71 [66-76] 139 71 [67-76] 33 69 [62-73] 0.030 Initial tumor staging 0.257

0.567 ISUP 2-3 (Gleason score 7) 148 40 (27.0) 113 30 (26.5) 30 10 (33.3)

Time CRPC to radium-223 [mo] 180 23.2 [12.0-37.9] 139 25.3 [12.0-38.0] 33 21.0 [10.7-35.0] 0.323

Opioid use 180 79 (43.9) 139 52 (37.4) 33 21 (63.6) 0.006

Enzalutamide 180 52 (28.9) 139 31 (22.3) 33 18 (54.5) <0.001

P value n median [IQR] or n (%) n median [IQR] or n (%) n median [IQR] or n (%)

ISUP 1 (Gleason score ≤ 6) 148 10 (6.8) 113 9 (8.0) 30 1 (3.3)

Localized prostate cancer 180 90 (50.0) 139 70 (50.4) 33 13 (39.4)

Metastatic prostate cancer 180 90 (50.0) 139 69 (49.6) 33 20 (60.6)

ISUP 4-5 (Gleason score ≥ 8) 148 98 (66.2) 113 74 (65.5) 30 19 (63.3)

Subgroup 4 (N=33)

Subgroups 1-3 (N=139)

6

Complete cohort (N=180)

Table 1. Baseline patient demographics and clinical characteristics.

Bone health agent use

161